Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2025)
Candel Therapeutics (CADL) posted Accumulated Expenses of $7.3 million for Q4 2025, up 185.37% sequentially from $2.6 million in Q3 2025, and up 43.44% YoY from $5.1 million in Q4 2024.
Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Accumulated Expenses for 6 years, with the latest figure at $7.3 million in Q4 2025.
- Quarterly Accumulated Expenses rose 43.44% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 43.44% YoY) and the FY2025 annual result came in at $7.3 million, up 43.44% from the prior year.
- Accumulated Expenses advanced to $7.3 million in Q4 2025 per CADL's latest filing, from $2.6 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $7.3 million in Q4 2025 and troughed at $1.1 million in Q2 2021.
- A 5-year average of $3.0 million and a median of $2.7 million in 2025 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 153.5% in 2024, down 58.42% in 2024.
- Over 5 years, Accumulated Expenses stood at $2.1 million in 2021, then gained by 26.29% to $2.6 million in 2022, then decreased by 23.8% to $2.0 million in 2023, then soared by 153.5% to $5.1 million in 2024, then jumped by 43.44% to $7.3 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $7.3 million, $2.6 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.33 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 5.11 Mn |
| Sep 30, 2024 | 4.57 Mn |
| Jun 30, 2024 | 3.22 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | 2.02 Mn |
| Sep 30, 2023 | 3.43 Mn |
| Jun 30, 2023 | 1.95 Mn |
| Mar 31, 2023 | 2.87 Mn |
| Dec 31, 2022 | 2.65 Mn |
| Sep 30, 2022 | 2.81 Mn |
| Jun 30, 2022 | 2.18 Mn |
| Mar 31, 2022 | 3.56 Mn |
| Dec 31, 2021 | 2.10 Mn |
| Sep 30, 2021 | 3.24 Mn |
| Jun 30, 2021 | 1.11 Mn |
| Dec 31, 2020 | 3.14 Mn |